Petvivo Holdings - PETVW STOCK NEWS

PetVivo Holdings (OTCQB: PETV) announced its participation in the Western Veterinary Conference (WVC) from March 2-5, 2025, at the Mandalay Bay Convention Center in Las Vegas. The company will showcase two key products: SPRYNG® with OsteoCushion® Technology, an intra-articular injectable veterinary device using sterilized, extra-cellular matrix microparticles for joint pain management, and PrecisePRP®, a novel off-the-shelf platelet-rich plasma product.

PrecisePRP® is notable for being leucoreduced, allogeneic, and requiring no blood draw or centrifugation, offering consistent dosing of 4 billion platelets per vial. The WVC, hosting over 15,000 participants, provides PetVivo an important platform to demonstrate these innovative solutions for osteoarthritis management in equine and companion animals.

PetVivo Holdings (OTCQB: PETV) reported fiscal Q3 2025 results with revenues of $583,000, up 191% sequentially but down 2% year-over-year. Distributor network sales reached $545,000, up 222% sequentially. The company maintained a strong gross margin of 89.5%, while operating loss improved by $375,000 to $1.8 million.

The company's lead product, Spryng with OsteoCushion Technology, is now used in over 800 veterinary clinics across all 50 states. PetVivo is shifting focus to include the larger companion animal market alongside its equine business, leading to sales force realignment. The company projects fiscal 2025 revenue of approximately $1.1 million, representing 10% growth.

Cash position stood at $29,000 as of December 31, 2024, but improved to $418,000 following a recent $1.1 million capital raise. Net cash used in operating activities decreased 31% compared to the previous year, reflecting improved operational efficiency.

PetVivo Holdings (OTCQB: PETV) has secured an Exclusive License and Supply Agreement with VetStem to commercialize PrecisePRP®, an innovative off-the-shelf platelet-rich plasma product for dogs and horses. This first-in-class product eliminates the need for blood draws or centrifugation, providing veterinarians with a consistent dose of 4 billion platelets per vial at 500,000 platelets per microliter.

The product undergoes rigorous safety screening according to FDA CVM Guidance 254, including infectious disease screening and blood type testing. Two randomized placebo-controlled safety studies revealed no treatment-related adverse events. PrecisePRP® will complement PetVivo's existing Spryng™ with OsteoCushion™ technology, reinforcing the company's position in veterinary medical devices and regenerative medicine.

PetVivo Holdings (OTCQB: PETV), a biomedical device company focused on commercializing innovative medical therapeutics for animals, has scheduled its Q3 FY2024 earnings release for Friday, February 14, 2025, after market close. The company will host a conference call and webcast to discuss the results at 2:00 p.m. CT (3:00 p.m. ET) on the same day.

Investors can access the live webcast through PetVivo's Investor Relations website, and a replay will be available following the conference call. The company has also provided dial-in details for those who prefer to join via phone.

PetVivo Holdings (OTCQB: PETV) has appointed Mike Eldred as Commercialization and Operations Advisor and Executive Director. Eldred brings 30 years of executive experience in animal health, notably serving as President of Dechra Pharmaceutical's North American Operations for 20 years, where he grew the subsidiary to over 250 employees and $400M+ in revenue.

The appointment aims to accelerate the adoption of Spryng™, PetVivo's intra-articular injectable veterinary medical device. Spryng uses OsteoCushion Technology, comprising sterilized extra-cellular matrix microparticles that integrate with animal subsynovial tissue to promote proper joint mechanics. Clinical studies have shown Spryng's effectiveness in treating lameness and joint-related conditions.

Prior to joining PetVivo, Eldred held senior positions at Virbac , Fort Dodge Animal Health, and Sanofi Animal Health, where he demonstrated success in business development, sales, and operations.

PetVivo Holdings (OTCQB: PETV) announced its participation in the Veterinary Meeting & Expo Conference from January 25-29, 2025, in Orlando, Florida. The company will showcase its flagship product, Spryng with OsteoCushion Technology, at booth #1825.

Spryng is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The product works by adsorbing onto animals' joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics. It's designed to manage noninfectious joint pain, including joint instability, degenerative joint disease, and osteoarthritis.

VMX, the largest veterinary conference in the United States, will provide PetVivo an opportunity to demonstrate Spryng's benefits to leading veterinarian surgeons and showcase its effectiveness in treating horses and companion animals across the U.S.

PetVivo Holdings (OTCQB: PETV) has announced new distribution partnerships with Vedco Inc. and Clipper Distributing, , both major players in veterinary product distribution. These partnerships will expand the distribution network for PetVivo's flagship product, Spryng™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device designed to manage joint pain in animals.

The partnerships connect PetVivo to major national veterinary product distributors including MWI, Covetrus, Patterson, Midwest Supply, and Penn Supply. Spryng is designed to promote joint pain management by augmenting and reinforcing cartilage to support normal joint function in cases where there is loss of cartilage or tissue-bone mechanical malfunction.

PetVivo Holdings (OTCQB: PETV and PETVW), a biomedical device company specializing in innovative medical therapeutics for animals, has announced a live webcast Shareholders Update Meeting scheduled for January 8, 2025 at 3:30 p.m. CT (4:30 p.m. ET).

The meeting will provide an overview of the company's progress in the 2025 fiscal year and discuss future prospects. Shareholders can access the webcast through PetVivo's Investor Relations website, and a replay will be available afterward. Additionally, participants can join via phone using the provided dial-in information.

PetVivo Holdings (OTCQB:PETV) has announced its participation in The Microcap Conference 2025, scheduled for January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. CEO John Lai will present a company overview and discuss their lead product, SPRYNG™ with OsteoCushion™ Technology.

SPRYNG is an intra-articular injectable veterinary medical device using sterilized, extra-cellular matrix microparticles. The product works by adsorbing onto animals' joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics and manage conditions like joint instability, degenerative joint disease, and osteoarthritis.